technology

Major breakthrough in search for HIV vaccine that could save millions of lives


A new test vaccine has shown promise (Picture: Getty)

A vaccine for HIV is a massive step closer following trials in the US in which a test jab triggered antibodies capable of neutralising the virus.

The immune response happened within weeks of a two-part vaccine being administered, raising hopes that a simple and commercial prevention is possible.

HIV, or human immunodeficiency virus, damages cells in the immune system, weakening the body’s ability to fight normal infections and disease. It can now be well managed using medication, but is still a leading cause of death in areas without adequate treatment.

A vaccine could save millions of lives worldwide.

While the test jab only triggered low levels of the antibodies, they were a type capable of fighting a range of HIV strains.

Senior author Dr Barton Haynes, from the Duke Human Vaccine Institute (DHVI), said: ‘This work is a major step forward as it shows the feasibility of inducing antibodies with immunisations that neutralise the most difficult strains of HIV.

‘Our next steps are to induce more potent neutralising antibodies against other sites on HIV to prevent virus escape. We are not there yet, but the way forward is now much clearer.’

Almost 40 million adults are currently living with HIV worldwide (Picture: Getty)

The antibodies target an area on the HIV pathogen’s outer layer called the membrane proximal external region (MPER), helping to block infection by the virus.

The trial involved 20 healthy, HIV-negative participants. Fifteen received two doses, and five received three.

After just two injections, participants showed strong immune activation.

Researchers initially planned to test four doses, but the trial was halted after one participant experienced a non-life-threatening allergic reaction, thought to be from an additive.

Readers Also Like:  This Amazon Black Friday deal gives you a Meta Quest 2 and a FREE £50 voucher



HIV testing

Shocking statistics earlier this year revealed that a fifth of Brits think they are unlikely to contract HIV despite rising cases among heterosexuals – include one million people who think they are immune.

The figures revealed that 73% of straight people in Britain have never been tested for the virus.

However, HIV testing is now quick and simple. There are several places to get a test, including:

  • sexual health or genitourinary medicine (GUM) clinics
  • clinics run by charities like the Terrence Higgins Trust
  • some GP surgeries
  • some contraception and young people’s clinics
  • local drug dependency services
  • an antenatal clinic, if you’re pregnant
  • a private clinic, where you will have to pay

And if you do not want to visit a clinic in person, there are also home sampling and home testing kits.

Lead author Dr Wilton Williams, also from Duke, said: ‘To get a broadly neutralising antibody, a series of events needs to happen, and it typically takes several years post-infection.

‘The challenge has always been to recreate the necessary events in a shorter space of time using a vaccine. It was very exciting to see that, with this vaccine molecule, we could actually get neutralising antibodies to emerge within weeks.’

To create the most robust vaccine, the team said it will need to target more regions of the envelope, and will likely have to attack at least three different parts of the virus.

‘Ultimately, we will need to hit all the sites on the envelope that are vulnerable so that the virus cannot escape,’ said Dr Haynes. ‘But this study demonstrates that broadly neutralising antibodies can indeed be induced in humans by vaccination.’

Readers Also Like:  Apple identifies issues causing overheating in the iPhone 15

The study is published in the journal Cell.


MORE : Brain diseases are getting worse as the planet gets hotter


MORE : Queen Camilla gives King Charles a telling off saying he needs to ‘behave himself’


MORE : What is it like to live with no internal monologue?





READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.